Trastuzumab emtansine 160mg powder for solution for infusion vials
NHS hospitals in England used £48,790,296 of indicative cost of Trastuzumab emtansine 160mg powder for solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 41.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Trastuzumab emtansine 160mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Trastuzumab emtansine 160mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Christie Nhs Foundation Trust | £8,794,278 |
| Royal Devon & Exeter Nhs Foundation Trst | £2,072,612 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,893,098 |
| Gloucestershire Hpls Nhs Foundation Trst | £1,480,613 |
| East And North Hertfordshire Nhs Trust | £1,410,982 |
| Royal Surrey County Hosp Nhs Found Trust | £1,340,143 |
| Derby Teaching Hospitals Nhs Found Trust | £1,072,618 |
| Sheffield Teaching Hospitals Nhs Trust | £1,068,732 |
| Imperial College Healthcare Nhs Trust | £1,056,891 |
| Barts Health Nhs Trust | £892,107 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.